Included in the formulation
АТХ:V.03.A.F Drugs that reduce the toxicity of cytostatic therapy
Pharmacodynamics:The preparation is a cyclic derivative ethylenediaminetetraacetic acid. Freely passes through the membrane of the cell, then it hydrolyzes and forms coordination bonds with divalent iron and with copper ions, resulting in a decrease in the formation of free radicals and doxorubicin complex with iron, which, in particular, participate in the development cardiomyopathy, induced anthracyclines. Thus, the drug exhibits cardioprotective properties. At the same time, the drug has no effect on the pharmacodynamics of anthracycline antibiotics.
Pharmacokinetics:When administered intravenously, plasma protein is 2%, the drug passes through the histohematological barrier and cumulates in the liver and kidneys. Eliminated by the kidneys, partly in the form of metabolites and partially unchanged (42%). Half-life is 2.5 hours.
Indications:Prevention of cardiomyopathy, cumulative chronic cardiotoxicity of anthracyclines (in cytotoxic therapy with anthracyclines in patients with favorable long-term prognosis,receiving radiotherapy at the same time; with recurrence of tumor disease after adjuvant chemotherapy with anthracyclines; with arterial hypertension; diabetes mellitus; in people over 65 years of age and children with cancer), Kaposi's sarcoma against AIDS (mono- or combination therapy).
I.B20-B24.B21.0 The disease caused by HIV, with manifestations of Kaposi's sarcoma
XIX.T36-T50.T45.1 Poisoning with antitumor and immunosuppressive drugs
Contraindications:Hypersensitivity.
Carefully:Chronic liver and kidney disease, childhood.
Pregnancy and lactation:Category FDA - C. The use of the drug during pregnancy and during breastfeeding is contraindicated.
Dosing and Administration:Introduction intravenous drip, infusion, simultaneously with chemotherapy anthracycline antibiotics.
Admission schedules for adults:
1) The drug is diluted to a concentration of 1.3-5 mg / ml in physiological saline or 5% glucose solution. Enter 500 mg / m2 half an hour before intravenous injection of doxorubicin.
2) The drug is diluted in water for injection (in 25 ml - stock solution), and then adjusted with Ringer's lactate solution to 250-500 ml.Enter in a dose of 1000 mg / m2 45-60 minutes before doxorubicin: infusion 20-30 minutes, then the same break.
Schemes of taking the drug for children:
When preparing the infusion solution, the required amount of the preparation is preliminarily diluted with phosphate buffer 0.488 M: at a dose of 0.5 g - 5 ml of buffer; 1 g - 10 ml; 1.5 g - 15 ml; 1.6 g - 16 ml; 1.7 g - 17 ml; 1.8 g - 18 ml; 1.9 g - 19 ml; 2 g - 20 ml, followed by the addition of an appropriate amount of water for injection.
Side effects:On the part of the hematopoiesis system: small (changing into average) leukopenia, small (changing into average) thrombocytopenia, anemia, decrease in hemoglobin of blood, vitamin B12, of serum iron.
From the coagulation system of the blood: bleeding disorder.
From the digestive system: nausea, vomiting, a transient increase in the level of hepatic enzymes, a transient increase in the content of triglycerides and amylase.
From the urinary system: an increase in the content of iron and zinc in the urine.
Other: malaise, a slight increase in body temperature, alopecia, a decrease in serum calcium levels. Less common is phlebitis at the injection site, black staining of the nails.
Overdose:Symptoms: leukopenia, thrombocytopenia, nausea, vomiting, diarrhea, skin reactions and alopecia.
Treatment: symptomatic. There is no special antidote.
Interaction:The drug enhances the myelotoxic effect of myelo-depressants (antitumor drugs and radiation therapy).
You can not mix the drug with other drugs in one bottle.
Special instructions:When taking the drug, cardiac monitoring is necessary.
Avoid contact with skin and mucous membranes, if swallowed, wash off with cold water.
Apply under the supervision of qualified specialists with experience in antitumor therapy.